| |
ViiV at IAS 2018 - ViiV Healthcare shares data from landmark 2-drug
regimen trials at AIDS 2018 - fostemsavir, DTG+3TC, DTG+RPV, Cabotegrvir
|
| |
| |
Full press release:
https://www.viivhealthcare.com/media/press-releases/2018/july/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018.aspx
London, 18 July 2018 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community.
John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, "As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with lifelong antiretroviral therapy. We look forward to sharing the primary endpoint 48-week data from the GEMINI 1 & 2 studies, that investigates a 2-drug regimen in treatment-naïve patients against a standard three-drug regimen; as well as 100-week data from the SWORD 1&2 studies for virologically-suppressed patients. AIDS 2018 will be an important moment in our innovative 2-drug regimen research and development programme, with results that affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more."
Data from a 2-drug regimen of dolutegravir and lamivudine in treatment-naïve patients
The GEMINI 1 & 2 phase III studies compare a 2-drug regimen of dolutegravir plus lamivudine to a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine. Primary endpoint results at 48-weeks showing efficacy of a dolutegravir and lamivudine 2-drug regimen compared to the three-drug regimen in treatment-naïve people living with HIV (PLHIV) will be presented.
100-week data from the 2-drug regimen of dolutegravir and rilpivirine (Juluca) in virologically-suppressed patients
The SWORD 1 & 2 phase III studies evaluated the safety and efficacy of switching virologically- suppressed PLHIV from a three- or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir and rilpivirine. The 148-week data will be shared in 2019.
Patient reported outcomes data for an investigational long-acting injectable regimen of cabotegravir and rilpivirine in virologically-suppressed patients
LATTE-2 is a phase IIb, open-label study investigating the 2-drug regimen of cabotegravir and rilpivirine, each in a long-acting, injectable formulation, for patients with HIV-1 infection who had already achieved viral suppression with a three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors. Data on adherence and satisfaction, tolerability and acceptability will be presented, supporting the goal of providing a long-acting regimen to PLHIV as an alternative to daily oral pills.
Key insights from partners of PLHIV
The international Positive Perspectives survey explores the impact an HIV diagnosis has on the quality of life, outlook and aspirations of PLHIV, and their partners. An analysis of responses from the partners of PLHIV will be presented at AIDS 2018.
The full list of data presented by ViiV Healthcare at AIDS 2018 is listed below:
|
|
| |
| |
|
|
|
